• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Video

Educational and Unmet Needs in GPP Management

Author(s):

David Kaplan, MD

An expert in dermatology shares his thoughts on the educational and unmet needs in the identification and management of patients with GPP.

Related Videos
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Related Content
Integrating Nonsteroidal Topical Therapies in Plaque Psoriasis Care
November 20th 2024

Integrating Nonsteroidal Topical Therapies in Plaque Psoriasis Care

The Cutaneous Connection: An Inside Look of the Inclusive Atlas
November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

AI-Powered Innovation: Zasocitinib’s Journey to Precision Inhibition
November 19th 2024

AI-Powered Innovation: Zasocitinib’s Journey to Precision Inhibition

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Quality of Life Severely Affected for Patients with GPP
November 5th 2024

Quality of Life Severely Affected for Patients with GPP

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis
October 27th 2024

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

© 2024 MJH Life Sciences

All rights reserved.